CSL Research Acceleration Initiative | Research Funding
Event details
| Date | 23.02.2023 |
| Category | Call for proposal |
Aim: CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life threatening medical conditions live full lives. CSL’s Research Acceleration Initiative aims to fast track discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts
for scientists working on novel biotherapeutic strategies in CSL’s therapeutic areas:
And that are amenable to or include a CSL modality:
Funding: max. 360’000 CHF
Duration: max. 24 months
How to Apply: Researchers who whish to apply are required to submit a non-confidential, 300-word online abstract.
Deadline: 23 February 2023
Further information
for scientists working on novel biotherapeutic strategies in CSL’s therapeutic areas:
- Immunology
- Hematology
- Respiratory
- Cardiovascular & Metabolic
- Transplant
- Vaccines
And that are amenable to or include a CSL modality:
- Antibodies
- Recombinant Proteins
- LV Gene Therapies
- Cell Therapies
- Adjuvanted Vaccines
- Cell-based vaccines
- sa-mRNA vaccines
Funding: max. 360’000 CHF
Duration: max. 24 months
How to Apply: Researchers who whish to apply are required to submit a non-confidential, 300-word online abstract.
Deadline: 23 February 2023
Further information
- Complete information can be found in the flyer (EPFL only; login with GASPAR credentials)
- For information on the webinar or application portal, or for any other questions, please contact Alboro De Pablo Peña from the Vice Presidency for Innovation
Practical information
- General public
- Free